For the second time, the U.S. Food and Drug Administration has refused to approve Replimune Group’s experimental skin cancer therapy, leaving patients with advanced melanoma who have run out of standard immunotherapy options without a new treatment they had been counting on.
The FDA delivered its decision through a complete response letter, a formal notice that an application does not yet meet the requirements for approval. The drug in question, RP1, is an oncolytic viral therapy designed to be injected directly into tumors that no longer respond to widely used anti-PD-1 checkpoint inhibitors. The agency first issued a complete response letter for RP1 in late 2024, citing concerns about the single-arm trial design underlying Replimune’s application. This second rejection deepens a dispute between Replimune and regulators over a core question: Can a clinical trial without a control group prove that a cancer drug actually works?
A virus engineered to fight cancer
RP1 is a genetically modified herpes simplex virus programmed to replicate inside tumor cells, destroying them while triggering a broader immune response. Replimune tested it alongside nivolumab, a checkpoint inhibitor sold by Bristol Myers Squibb under the brand name Opdivo, in a trial called IGNYTE.
The IGNYTE study used a single-arm design, meaning every patient received the RP1-nivolumab combination and no group received an alternative treatment for comparison. The primary measure of success was objective response rate: the share of patients whose tumors shrank by a predefined amount. Results were published in the Journal of Clinical Oncology, reporting an objective response rate of approximately 34% among patients whose melanoma had progressed after prior anti-PD-1 therapy, with a majority of responses lasting six months or longer according to the published data. The paper confirmed that the combination produced meaningful tumor responses in a population with limited remaining options.
Replimune has stated publicly that it disagrees with the FDA’s assessment and believes the IGNYTE data support approval. The company has characterized the agency’s position as inconsistent with precedents for accelerated approval in oncology, though the FDA has not commented publicly on the specifics of its decision beyond the confidential complete response letter.
Why the FDA said no, twice
The agency’s complete response letter reportedly cited concerns about the single-arm design’s ability to prove that RP1 itself drove the tumor responses observed in IGNYTE. Without a comparator group, regulators could not rule out the possibility that patients might have responded similarly to other available treatments or that selection bias influenced the results.
This is not a new tension in oncology. The FDA has historically granted accelerated approvals based on single-arm data when patients face life-threatening conditions with few alternatives. But the agency has also grown more cautious in recent years, withdrawing several accelerated approvals when confirmatory trials failed to verify benefit. That shifting regulatory climate appears to have caught Replimune in a difficult position: the company pursued a path that might have succeeded a few years earlier but now faces a higher evidentiary bar.
The full text of the complete response letter remains confidential. The specific statistical and methodological objections the FDA raised are known only through Replimune’s own disclosures and secondary reporting, not from the agency’s original document. That means public descriptions of the rejection capture the broad strokes but may miss important details about what regulators found most problematic.
The randomized trial that could change the outcome
Replimune has already launched a follow-up study designed to answer the FDA’s objections directly. The Phase 3 trial, called IGNYTE-3, randomizes patients to receive either RP1 plus nivolumab or a physician’s choice of alternative therapy. It targets a narrower population than the original study: patients whose advanced melanoma has progressed after both anti-PD-1 and anti-CTLA-4 checkpoint inhibitors, a group with even fewer remaining options.
The two trials differ in ways that matter for interpreting future results. IGNYTE enrolled a broader set of patients and measured tumor shrinkage without a control group. IGNYTE-3 uses randomization, a defined comparator arm, and prespecified endpoints that align with what regulators typically require for full approval. Readers following this story should be careful not to conflate the two protocols, since Replimune’s regulatory future now hinges on the newer, more rigorous study.
The critical unknown is timing. Based on the trial’s registry listing, IGNYTE-3 appeared to be in its early stages of enrollment relative to the study’s planned patient count as of the most recent publicly available update. If recruitment continues at a slow pace, the randomized data the FDA wants could be years away, prolonging the wait for patients and raising questions about whether the trial can reach the statistical power needed to deliver a definitive answer.
What this means for patients with treatment-resistant melanoma
For people living with advanced melanoma that has stopped responding to checkpoint inhibitors, the practical reality of this second rejection is stark. RP1 will not be available through a standard prescription. Access is limited to enrollment in IGNYTE-3 or any expanded-access programs Replimune may offer.
The unmet need in this population is real. Patients who progress after anti-PD-1 and anti-CTLA-4 therapies face a shrinking list of options, and response rates to later-line treatments tend to be low. That urgency is precisely why Replimune pursued a single-arm trial in the first place: to get a promising therapy to patients faster. But the FDA’s repeated insistence on randomized evidence signals that speed alone will not be enough to clear the regulatory bar, no matter how desperate the clinical situation.
The path forward now runs through IGNYTE-3. If the randomized trial demonstrates a clear benefit over physician’s choice therapy and meets its prespecified endpoints, Replimune will have the comparative data regulators have twice said they need. Until those results arrive and undergo formal FDA review, RP1 remains an experimental drug in a space where patients are running out of time and the agency is holding firm on the evidence it requires to say yes.
More from Morning Overview
*This article was researched with the help of AI, with human editors creating the final content.
